Last $30.28 USD
Change Today -0.22 / -0.72%
Volume 838.5K
NPSP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

nps pharmaceuticals inc (NPSP) Snapshot

Open
$30.67
Previous Close
$30.50
Day High
$30.98
Day Low
$30.21
52 Week High
02/25/14 - $39.68
52 Week Low
07/15/13 - $17.38
Market Cap
3.2B
Average Volume 10 Days
1.3M
EPS TTM
$-0.13
Shares Outstanding
106.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NPS PHARMACEUTICALS INC (NPSP)

nps pharmaceuticals inc (NPSP) Related Businessweek News

View More BusinessWeek News

nps pharmaceuticals inc (NPSP) Details

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company also develops Natpara that is under Phase 3 clinical trial for the treatment of adult hypoparathyroidism; NPSP790 and NPSP795 calcilytic compounds, which are in Phase 1 clinical trial for application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria; and Teduglutide that is under preclinical stage for pediatric indications. It has collaborative agreements with GlaxoSmithKline to collaborate on the research, development, and commercialization of calcium receptor active compounds to treat osteoporosis and other bone metabolism disorders; and Kyowa Hakko Kirin Co. Ltd. to develop and commercialize compounds for the treatment of hyperparathyroidism. The company was founded in 1986 and is based in Bedminster, New Jersey.

207 Employees
Last Reported Date: 02/18/14
Founded in 1986

nps pharmaceuticals inc (NPSP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $413.7K
Senior Vice President and President of NPS Ph...
Total Annual Compensation: $395.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $407.9K
Vice President of Corporate Development & Str...
Total Annual Compensation: $223.1K
Compensation as of Fiscal Year 2013.

nps pharmaceuticals inc (NPSP) Key Developments

FDA Approves Updated Labeling for NPS Pharmaceuticals, Inc.'s Gattex for Injection to Include Long-Term Data

NPS Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Gattex(R) (teduglutide [rDNA origin]) for injection to include long-term data from the STEPS 2 study of adult patients with Short Bowel Syndrome (SBS). The data demonstrate that patients who continued Gattex treatment beyond two years achieved clinically meaningful reductions in parenteral support requirements, including volume and days off, with 13 out of 88 patients across all groups achieving complete independence. In the U.S., Gattex is indicated for the treatment of adult patients with SBS who are dependent on parenteral support. The STEPS 2 study demonstrated that there was an increased response to treatment over time in all groups receiving Gattex in terms of volume reductions, days off and complete weaning of parenteral support.

NPS Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 10:00 AM

NPS Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 10:00 AM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Francois Nader, Chief Executive Officer, President and Director.

Shire Reportedly Secures Funding To Acquire NPS Pharma

Shire plc (LSE:SHP) has secured a $5 billion credit facility for a takeover offer for NPS Pharmaceuticals, Inc. (NasdaqGS:NPSP), The Times of London reported. The newspaper said Shire has lined the credit facility for NPS, which is being advised by Goldman Sachs, from banks led by Citigroup. Insiders told The Times that an initial approach to NPS by Shire has been rebuffed. However, a former London hospital doctor with ties to both companies is acting as a go-between, the daily said.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPSP:US $30.28 USD -0.22

NPSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NPSP.
View Industry Companies
 

Industry Analysis

NPSP

Industry Average

Valuation NPSP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.0x
Price/Book 29.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NPS PHARMACEUTICALS INC, please visit www.npsp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.